Acasti Pharma Inc. (ACST): Company Cash Volume

Corporate company logo of acastipharma.com (ACST)

Acasti Pharma cash asset dynamics are driven by the outsourcing of production and clinical operations to third-party contractors, as well as a licensing approach to the distribution of cardiology developments. The value 0.02 is recorded as the baseline liquidity value. Current capital relies on the search for strategic partners to commercialize treatments for rare pathologies and the successful completion of trials for ataxia drugs.

ACST - Acasti Pharma Company Cash Volume over the range 07/04/2022 - 10/28/2024

Analytical breakdowns and data insights for company Acasti Pharma Inc. (ACST)

- stock value and consensus price forecast:
- stock exchange capitalization data:
Summary company analysis:Acasti Pharma
Signature product of acastipharma.com

The margin of safety for Acasti Pharma (ACST) is determined by the volume of liquid assets, which eliminates the need for secondary offerings. A stable reputation as a developer of rare therapies allows the company to attract capital based on trust. Analyzing this cash liquidity chart, an investor can see the actual resources available to fund R&D without incurring a debt load. This metric measures the business's ability to autonomously sustain its operating activities, characterizing the asset as a defensive instrument with moderate risk.